FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
This article was originally published in The Pink Sheet Daily
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.
You may also be interested in...
PDUFA renewal could establish process that allows firms early warnings about Sentinel and other safety data announcements.
Endocrinologists raise concerns over FDA case reports because diabetic ketoacidosis may be a risk for type 1 diabetes patients taking SGLT2 inhibitors, but it is very rare in type 2 diabetes.
J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.